SNPX, 中重度老年痴呆的希望

beyondBet

谢谢楼上，你说的是BIIB， 3期数据一般般，FDA 手里无粮，饿急了的话，估计也会有限批

我这两月速成了AD业余圈专家，主要是前2月被SAVA刺激到，一个因为安慰剂变化太大都已经失败了的双盲2期，cook 一下数据，居然能冲过2B， 市场也是饿晕了哈

beyondBet

对 SAVA 数据的质疑

SAVA's trials, no any result available to public， 点开link， check result tab ，all nothing:

Phase 1: 8/18/2017 - 10/9/2017 NCT03784300 https://clinicaltrials.gov/ct2/show/NCT03784300

24 participants， this phase 1 trial was initially on Pain Therapeutics (not AD, but luckily ended up with a huge success on AD) , double-blind, placebo controlled

phase 2a: 3/7/2019 - 5/8/2019 NCT03748706 https://clinicaltrials.gov/ct2/show/NCT03748706

open-label study of PTI-125 in mild-to-moderate AD patients, 12 participants

Phase 2b: 9/9/2019 - 3/31/2020 NCT04079803 https://clinicaltrials.gov/ct2/show/NCT04079803

Double-blind, Placebo-controlled, Multiple Dose, 64 participants

Phase 2: 3/24/2020 - 3/31/2022 NCT04388254 https://clinicaltrials.gov/ct2/show/NCT04388254 Open Label

我被SAVA脚踝斩过， 去年三月$4块多买的，五月开胡直接脚踝到$1.6,  当时出的 Top-line Results from a Phase 2b Study of PTI-125 in Alzheimer’s Disease Does Not Meet Primary Endpoint May 15, 2020 太有印象了，败在安慰剂上：“A post-hoc analysis of biomarker data revealed high variability in levels of CSF biomarkers over 28 days. For example, placebo-treated patients recorded changes in levels of CSF tau and p-tau ranging from -54% to +34% and -49% to +253%, respectively ” （后来细看傻娃挑病人的标准来看，败给安慰剂一点不意外 ）， 可是4个月过去，这同一组数据搞出了一份近乎完美的PPT https://www.cassavasciences.com/ ... 8-9f8f-af122d13a445





五月份的时候，明明是败在安慰剂数据变化太大的，九月份图上的placebo居然这么完美无瑕啊，几乎都压到0了，同学们，我就是僵在这里转不过弯了，去掉了几个最高分几个最低分？以什么标准去掉的？后面的trial， 直接open label， 彻底甩掉了安慰剂的麻烦。

再说说SAVA挑选病人的标准，要干过control 是非常不容易的，需要art , 就像 phase2b， 不光试验前期要仔细挑人，出了结果，还得仔细挑人哈，后面的试验干脆open label 算了，不必遮掩：

Additional Criteria for NEW patients:

                     The patient has a ratio of total tau/Aβ42 in cerebrospinal fluid >= 0.28.

                     MMSE score >= 16 and <=26 at screening, OR if > 26, must have evidence of AD pathology such as a prior CSF total tau/AB42 ratio >=0.28, an amyloid  positive PET scan or hippocampal volume loss consistent with AD.

我很意外股票市场居然这么买账，能一路冲到$138, 根本想不到。我在$30， $60 就开始分批卖了，最后在130卖了大部分，只留了小部分等待见证奇迹。见到这个疯狂，也出于对SAVA的不信任，我很快扫荡式 搜查到新欢SNPX 。

beyondBet

我扫过的AD 生药：

有些不在Naz, 有些没上市

ACIU  ADMS  ALEC  Alzheon Amylyx  ANVS ATHA

Avanir/Otsuka  AVXL  BIIB Cognition  Cognito   CRTX  DNLI

INMB  NeuroEM  Neurotez  SAVA   TNXP   VTVT

最爱SNPX， 便宜哈

beyondBet

还有些最近已经失败了， 还有几个大药厂的， 不能high起来的就不贴了

beyondBet

beyondBet 发表于 2021-4-4 10:06 AM
我扫过的AD 生药：

有些不在Naz, 有些没上市

说的不对， SNPX 是 又好又便宜

当时惘然

beyondBet 发表于 2021-4-4 10:02 AM
谢谢楼上，你说的是BIIB， 3期数据一般般，FDA 手里无粮，饿急了的话，估计也会有限批

我这两月速成了AD ...

你说的对！
现在都着等6月的FDA决定.
几个月前panel专家的意见并不看好biib的三期临床数据。
但是考虑到已经有17年没有批准新药物的市场压力。
fda也许会网开一面，有条件批准。
原本是准备延期到4月份出最终决定的，后来又再次延期到6月份。
我预计获批的可能性在20%左右。

ad症的药物研发，以往17年的历史经历都说明了，再厉害的团队再巨量的资金投入，都是100%的失败！
更何况是你提到的这家资金不太大的小药厂呢……

有些巨富们投资给它，只是花费自己身家的1%左右，不成功也无所谓。如果成功了，那就是几十倍的回报。
我个人对这些小药厂不是特别看好，ymyd……

beyondBet

谢谢楼上提醒，你们这里的打分打赏什么的，很好玩啊，我还不会用

beyondBet

来胡同更新一下SNPX近报　－－

昨天出了一份  SEC form S-1A  , amended registration statement，专门细说股权，太细说了，快进到68-71页，私募的７７位大小股东一个不漏全暴露了，哈哈。

As of April 7, 2021, we had 14,032,516 outstanding shares of Common Stock issued and outstanding held by approximately 270 stockholders of record.

我做了一点简单加法, 重大发现是，SNPX真正意义的流通股，咱们小散有可能买来买去的流通股，居然还不到１M shares,  adding those private offering + insider holding , already ~ 33M shares , out of total 33,970,468  shares  of  Common  Stock  outstanding,  which  assumes  the  issuance  and  sale  of  19,937,952  shares  of  Common  Stock,  upon  full exercise of the Investor Warrants, Pre-Funded Warrants and Placement Agent Warrants .　

现在一共有１4M 流通股，但绝大多数在私募手里，这些早期就开始死忠的私募粉，我觉得他们不会在２块钱亏钱卖股的。减掉私募持股，减掉员工持股（很少），只剩下１百万不到的真正意义的流通股 。　

我给私募的那７７个股东略估了他们的均价，最好的是2020年一月入股的，均价$2.57; 要是入股早的死忠粉，更是５块，１０块了，生药研发不容易，粉丝不好当的。

我挑重点再说几点吧：

１.　这个季度烧钱好快，100个病人的phase 2 trial, 已经付了$10M； 申请Nasdaq 上市，申请费用以及为此耗资准备的股东会，也花了好多钱。不过，现有的资金，加上一年期和五年期的warrants，足够烧到2022年底，可以撑完 AD phase 2b 和另外一个Fragile X 的phase1 trial。
It's from the January money raise. 9+ million of the 28+ million is already factored in to the 14+ million current O/S. Another 9+ million warrant shares can only be redeemed within 12 months of this past January. Those are priced above $2 so will bring in tons of cash if utilized. The remaining 9+ million, if ever exercised, would bring in tons more cash. 37+ million dollars if totally utilized and bring the total O/S count to approx 32 million shares. Net, net is we have 14 million o/s currently. 9+ million come off the books next year one way or another and then we can only guess how many of the last warrant class will be used.

２.　这是warrents 细节：
这部分是NTRP遗留过来的，全都亏废了
157,791 Series A Warrants to purchase up to 157,791 shares of Common Stock with an exercise price of $49.41 per share ；
623,250 Series B Warrants to purchase up to 623,250 shares of Common Stock with an exercise price of $19.76 per share ；
906,264 Series C Warrants to purchase up to 906,264 shares of Common Stock with an exercise price of $9.88 per share;
and 2,221,820 Series D Warrants to purchase up to 2,221,820 shares of Common Stock with an exercise price of $3.95 per share.
下面是1/21/2021 新发的warrents, 主力买家还是上面亏死过的同一拨死忠粉，我一点不介意签的价钱是$1.725, $2.1275：
(ii) an aggregate of up to 9,335,533 shares of Common Stock that are issuable upon the conversion of the Series E Warrants;
(iii) an aggregate of up to 9,335,533 shares of Common Stock that are issuable upon the conversion of Series F Warrants;
(iv) an aggregate of up to 333,333 shares of Common Stock that are issuable upon the conversion of the Pre-Funded Warrants;
and (v) an aggregate of  933,553  shares  of  Common  Stock  that  are  issuable  upon  the  conversion  of  the  Placement  Agent Warrants.
记得有看到，如果股价超过５块，公司有权力取消up to 50%的warrents, 时限记不清了。还记得有一条专门对付恶意收购，说任何个人或机构，持股超过15%的话，所有股东（当然15%的除外）拥有以市场价一半的价钱，购入同样股数的权力。蛮好玩的，我不知道这会是什么样的骚操作，估计以恐吓为主。

３.　研发专利，NTRP前身的洛克菲勒基金（10几年一共投入过$200M研发资金）将拥有部分未来商业利润的1.5% - 5% ，跟咱们报税一样，阶梯上升。

beyondBet

最让我笃定的是，short没地方跑了，我这一个多月买进的SNPX，大部分是short强行砸给俺的。S-1A form 上的７７位股东拥有的SNPX，全部泡水里了好几年了，不可能在这个价位亏钱卖，新的一场戏大幕即将徐徐打开，今年肯定先不急的。我自己攒的，加上我知道的yahoo上的几个队友攒的，剩下的零头，已经不够cover 300K+ short position 了。同学，珍惜你拥有的戏票吧

           Short Volume      Short Volume Ratio
2021-04-09        5,237        43.49
2021-04-08        600                3.51
2021-04-07        8,638        28.57
2021-04-06        14,602        24.06
2021-04-05        39,519        70.97
2021-04-01        15,470        35.04
2021-03-31        19,672        38.45
2021-03-30        2,480        12.26
2021-03-29        11,980        62.00
2021-03-26        17,191        41.68

accumulated short interest:
03/31/2021        241,690       
03/15/2021        195,495       
02/26/2021        188,666       
02/12/2021        188,930       
01/29/2021        164,423       

春风杨柳，满目新绿

beyondBet

SNPX，统共只有２７０位股东，私募７７位，　管理层＋员工１０来个，大千大概有５０来个，我还知道yahoo版上１０来位，不知道胡同有几位　

deep

beyondBet 发表于 2021-4-14 11:37 PM
SNPX，统共只有２７０位股东，私募７７位，　管理层＋员工１０来个，大千大概有５０来个，我还知道yahoo版 ...

队伍不好带啊

beyondBet

deep 发表于 2021-4-15 10:41 AM
队伍不好带啊

我被short　砸的满头包的苦日子快熬出来了　

beyondBet

敌人上周五和今天都在疯狂反扑，已经是打明牌了，现有的419K short position, 已经没有足够的 "real" floating shares to cover ---

Based on the data I collected and calculated, up today, there are total 419,713 shares of short position.

According to the latest Sec form S-1A  on 4/13/2021, there are total 32,482K shares of private holding, out of total 33,970,468 shares  of  Common Stock  outstanding  ( assuming future issuance  of  19,937,952  warrants) ,
insider holding ~ 250K, so it left with  only 1,238K , the "real" floating shares, available for all retail investors.

Combining the shares I have accumulated in the past 2 months ( yes, I bought SNPX everyday), plus the shares my friends have accumulated so far, it's already short of enough "real" floating shares available to fully cover
current 419K short position.

beyondBet

SNPX weekly short position update:

Latest Market Date 2021-04-16
Short Volume 49,909
Market Volume 99,684
Short Volume Ratio 50%


Last Change Timestamp (UTC) Short Shares Availability
7m 2021-04-19 12:44:36.813 10,000
1h 2021-04-19 11:23:49.8 2,000
04-12 2021-04-12 16:52:51.515 1,000
04-09 2021-04-09 09:51:00.941 400
04-08 2021-04-08 11:35:02.963 100
04-07 2021-04-07 12:27:53.714 5,000
04-07 2021-04-07 11:25:54.514 100
04-06 2021-04-06 12:07:34.007 1,000
04-01 2021-04-01 07:57:19.053 100
03-30 2021-03-30 12:33:56.088 1,000
03-29 2021-03-29 09:45:48.878 500
03-19 2021-03-19 11:28:52.792 2,000
03-19 2021-03-19 05:41:22.099 10,000       1:41am      
03-18 2021-03-18 15:45:52.926 8,000        11:45am      
03-18 2021-03-18 15:02:41.391 9,000        11:02am      
03-18 2021-03-18 11:37:55.809 8,000        7:37am      
03-18 2021-03-18 10:05:08.444 300          6:05am      

Last Change Timestamp (UTC) Short Borrow Fee Rate (%)
1h 2021-04-19 11:23:49.8 5.88
04-12 2021-04-12 16:52:51.515 8.06
04-09 2021-04-09 16:34:19.304 5.64
04-09 2021-04-09 14:30:30.477 6.79
04-08 2021-04-08 14:41:00.804 7.07
04-07 2021-04-07 21:38:38.721 6.88
04-07 2021-04-07 20:36:28.238 6.89
04-07 2021-04-07 16:28:05.219 6.90
04-07 2021-04-07 14:31:58.704 7.05
04-06 2021-04-06 16:46:10.139 7.41
04-06 2021-04-06 14:42:23.075 7.29
04-06 2021-04-06 12:07:34.007 7.98
04-01 2021-04-01 07:57:19.053 9.22
03-30 2021-03-30 21:42:26.657 8.96
03-30 2021-03-30 18:36:41.011 7.29
03-30 2021-03-30 16:41:35.508 6.39
03-30 2021-03-30 14:37:47.356 6.62
03-29   2021-03-29 18:33:36.389 5.86
03-29   2021-03-29 14:26:06.852 7.36


Short Volume     Short Volume Ratio
2021-04-16 49,909  50.07
2021-04-15 11,804    59.71
2021-04-14 26,444 55.57
2021-04-13 3,500 48.34
2021-04-12 2,300    44.79
2021-04-09 5,237 43.49
2021-04-08 600        3.51
2021-04-07 8,638 28.57
2021-04-06 14,602 24.06
2021-04-05 39,519 70.97
2021-04-01 15,470 35.04
2021-03-31 19,672 38.45
2021-03-30   2,480   12.26
2021-03-29 11,980 62.00
2021-03-26 17,191 41.68
2021-03-25  7,978 49.70
2021-03-24  4,425 56.90
2021-03-23  3,945 43.24
2021-03-22 10,895   71.05
2021-03-19 11,965   83.83
2021-03-18  5,321    99.25
2021-03-17  24,079 76.87

Date Short Interest Days to Cover
2021-03-31 241,690 8.04
2021-03-15 195,495 2.43
2021-02-26 188,666 5.67
2021-02-12 188,930 1.00
2021-01-29 164,423 1.00
2021-01-15 5,110 1.00
2020-12-31 3,918 1.00
2020-12-15 4,831 1.00

Fails-To-Deliver    Update Frequency: Daily
Date Price Quantity
2021-03-10 2.23 961
2021-03-09 1.80 22
2021-03-08 1.80 2
2021-03-03 2.28 24
2021-03-02 2.35 36
2021-03-01 2.29 1
2021-02-26 2.40 696
2021-02-25 2.47 828
2021-02-24 2.48 13
2021-02-23 2.60 17
2021-02-22 2.78 275
2021-02-16 2.80 386
2021-02-12 2.86 387
2021-02-11 3.22 2,351
2021-02-10 2.90 1,000
2021-02-09 2.40 1,000
2021-02-08 2.20 800
2021-02-02 1.25 46,661
2021-02-01 1.31 3,171
2021-01-27 1.45 99

beyondBet

哇， 谢谢 Cobra 斑竹置顶 ！

我来胡同的第一帖，从刚浮出水面到现在，一直都受到胡同同学的宽容款待，真的是真心感谢啊 ~~

在大千，好多人鄙视我吆喝垃圾股，居心不良；在华人，连贴过两次，每次都是连根拔了，后来逼的我装逼贴英文，英文版活下来后，我才敢贴中文，美其名曰“方便大家阅读“。

我也注册了 stocktwits， 已经被连封三次， 我一直秋菊打官司， 一次一次又一次的 Appeal an account suspension， 还在等呢。stocktwits 的规矩不平等， existing community member can flag newbie and block me out, 我觉得就是SNPX的 几个short 把我 flag 给赶出来的。

总之，就是个流浪狗。胡同 海纳百川，有气度 ， 这里应该有个大拇指，可惜没找到图标 ~~

Cobra

beyondBet 发表于 2021-4-19 07:46 PM
哇， 谢谢 Cobra 斑竹置顶 ！

我来胡同的第一帖，从刚浮出水面到现在，一直都受到胡同同学的宽容款待， ...

可能他们觉得你是在pump SNPX，这种情况很多的。我不介意谁pump什么股，只要有理有据就行。你这看上去花了不少时间搜集资料。

评分是这样的，每个贴（包括回帖）底下都有评分。评分发的钱是凭空印出来的，不是你的钱，所以你可以随便给，不能超过你每天评分的上限，不过，否则胡同的胡币就太泛滥了，现在其实就已经很泛滥了，呵呵。

beyondBet

谢谢斑竹，学会打分了

beyondBet

beyondBet 发表于 2021-4-14 11:31 PM
来胡同更新一下SNPX近报　－－

昨天出了一份  SEC form S-1A  , amended registration statement，专门 ...

4/16/2021  上周五统计，被空了419,713 shares of short position， 真正意义的流通股 只有1.238M，

今天买来的数据看到， 今天至少又borrow 了 一万九千股：

New short position borrowed today:
1h 2021-04-19 20:29:48.126 7,000
8h 2021-04-19 12:44:36.813 10,000
10h 2021-04-19 11:23:49.8 2,000

Short Borrow Fee Rate (%)
1h 2021-04-19 20:29:48.126 9.71
10h 2021-04-19 11:23:49.8 5.88

做空率已经35%了

beyondBet

秋菊打官司，赢啦， 好开心，终于可以言论自由。我被封3次，第一次和第三次是被人举报， 第二次是软件自动封的 -- 刚解封就轮番灌水行迹可疑

我的申请状子，to appeal an account suspension：

Hi there,

I have read the house rules and best practices, all rules made good sense to me and I truly respected them. I don't think I offended any rules, but if my message was reported by a member in the community, he/she must be short on SNPX. There is a group of people who kept shorting this emerging biotech for over 2 years ( SNPX was called NTRP last year), kept shorting the company focused on research in a long journey fighting with Alzheimer's Disease.

Is there any consequence if a person kept flagging a new member without any solid evidence please? I have been suspended three times already, without breaking any of your house rules.

All my messages came from public online info, for example,  

1). for trials part, from public government database:

Phase 1/2-201 6/2014 - 12/2014 https://clinicaltrials.gov/ct2/s ... p;draw=2&rank=1

Phase 2-202 : 11/2015 - 2/2017 https://clinicaltrials.gov/ct2/show/study/NCT02431468

Phase 2-203: 6/20/2018 - 7/25/2019 https://clinicaltrials.gov/ct2/show/NCT03560245

Phase 2-204: 8/30/2020 - 11/2/2022 https://clinicaltrials.gov/ct2/show/NCT04538066


2). for research part, all from academic publications:
Activation of Protein Kinase C Isozymes for the Treatment of DementiasPharmacology of protein kinase C activators: Cognition-enhancing and antidementic therapeutics
Miao-Kun Sun, Daniel L. AlkonPKC ε Activation Prevents Synaptic Loss, Aβ Elevation, and Cognitive Deficits in Alzheimer’s Disease Transgenic Mice
Jarin Hongpaisan, Miao-Kun Sun, and Daniel L. AlkonPKC signaling deficits: a mechanistic hypothesis for the origins of Alzheimer’s disease
Daniel L. Alkon, Miao-Kun Sun and Thomas J. NelsonNeuroprotective versus tumorigenic protein kinase C activators
T.J. Nelson and D.L. AlkonPKC signaling deficits: a mechanistic hypothesis for the origins of Alzheimer’s disease
Daniel L. Alkon, Miao-Kun Sun and Thomas J. NelsonAdduct formation in liquid chromatography-triple quadrupole mass spectrometric measurement of bryostatin 1
Thomas J. Nelson, Abhik Sen, Daniel L. Alkon, Miao-Kun SunPKCε Promotes HuD-Mediated Neprilysin mRNA Stability and Enhances Neprilysin-Induced Ab Degradation in Brain Neurons
Chol Seung Lim, Daniel L. AlkonBryostatin-1 Restores Hippocampal Synapses and Spatial Learning and Memory in Adult Fragile X Mice
Miao-Kun Sun, Jarin Hongpaisan, Chol Seung Lim, and Daniel L. Alkon
PKC activation during training restores mushroom spine synapses and memory in the aged rat
Jarin Hongpaisan, Changqing Xu, Abhik Sen, Thomas J. Nelson, Daniel L. Alkon
Synergistic effects of chronic bryostatin-1 and α-tocopherol on spatial learning and memory in rats
Miao-Kun Sun, Daniel L. AlkonPostischemic PKC activation rescues retrograde and anterograde long-term memory
Miao-Kun Sun, Jarin Hongpaisan, and Daniel L. AlkonNeuroprotective versus tumorigenic protein kinase C activators
T.J. Nelson and D.L. AlkonReduction of β-Amyloid Levels by Novel Protein Kinase Cε Activators
Thomas J. Nelson, Changhai Cui, Yuan Luo, and Daniel L. AlkonA cellular model of Alzheimer’s disease therapeutic efficacy: PKC activation reverses Aβ-induced biomarker abnormality on cultured fibroblasts
Tapan K. Khana, Thomas J. Nelson, Vishal A. Verma, Paul A. Wender, and Daniel L. AlkonSynergistic effects of chronic bryostatin-1 and α-tocopherol on spatial learning and memory in rats
Miao-Kun Sun, Daniel L. Alkon
Analysis of long-term cognitive-enhancing effects of bryostatin-1 on the rabbit (Oryctolagus cuniculus) nictitating membrane response
Desheng Wang, Deya S. Darwish, Bernard G. Schreurs, and Daniel L. AlkonPKC signaling deficits: a mechanistic hypothesis for the origins of Alzheimer’s disease
Daniel L. Alkon, Miao-Kun Sun and Thomas J. NelsonProtein synthesis required for long-term memory is induced by PKC activation on days before associative learning
Daniel L. Alkon, Herman Epstein, Alan Kuzirian, M. Catherine Bennett, and Thomas J. NelsonTherapeutic effects of PKC activators in Alzheimer’s disease transgenic miceDiscrimination Learning Alters the Distribution of Protein Kinase C in the Hippocampus of Rats
James L. Olds, Stephanie Golski, Donna L. McPhie, David OKon, Mot-timer Mishkin and Daniel L. AlkonlClassical conditioning induces long-term translocation of protein kinase C in rabbit hippocampal CAl cells (memory storage/membrane-associated protein kinase)
BARRY BANK, ANN DEWEER, ALAN M. KuZIRIAN, HOWARD RASMUSSEN, AND DANIEL L. ALKONA cellular model of Alzheimer's disease therapeutic efficacy: PKC activation reverses
Aβ-induced biomarker abnormality on cultured fibroblasts
Tapan K. Khan, Thomas J. Nelson, Vishal A. Verma, Paul A. Wender, Daniel L. AlkonThe maddening saga of how an Alzheimer’s ‘cabal’ thwarted progress toward a cure for decadesPKC epsilon Promotes Synaptogenesis through Membrane Accumulation of the Postsynaptic Density Protein PSD-95 J Biol Chem. 5;291(32):16462-76, 2016 Abhik Sen, Jarin Hongpaisan, Desheng Wang, Thomas J. Nelson and Daniel L. AlkonRescue of Synaptic Phenotypes and Spatial Memory in Young Fragile X Mice. J. Pharmacol. Exp. Ther. 357: 300-310, 2016Miao-Kun Sun, Jarin Hongpaisan, and Daniel L. AlkonApoE4 and Aβ Oligomers Reduce BDNF Expression via HDAC Nuclear Translocation Neuroscience 35(19): 7538-7551; doi: 10.1523 /JNEUROSCI. 0260-15.2015 Abhik Sen, Thomas J. Nelson and Daniel L. AlkonApolipoprotein E3 (ApoE3) but Not ApoE4 Protects against Synaptic Loss through Increased Expression of Protein Kinase Cε. J Biol Chem 287(19), 15947-15948, 2012. Sen A, Alkon DL, Nelson TJPKCε Activation Prevents Synaptic Loss, Aβ Elevation, and Cognitive Deficits in Alzheimer's Disease Transgenic Mice, Journal of Neuroscience, 31(2):630–643, 2011. Hongpaisan, J., Sun, MK, Alkon DLPostischemic PKC activation rescues retrograde and anterograde long-term memory. (Proc Nat. Acad. Sci. USA) 106 (34): 14676–14680, 2009. Sun, MK, Hongpaisan, J, Alkon, DLA structural basis for enhancement of long-term associative memory in single dendritic spines regulated by PKC. Proc Natl Acad Sci USA 104 (49): 19571-19576, 2007. Hongpaisan J, and Alkon DLTowards universal therapeutics for memory disorders. Trends in Pharmacological Sciences, June 2015, Vol. 36, No. 6. Miao-Kun Sun, Thomas J. Nelson, and Daniel L. AlkonPKC activator therapeutic for mild traumatic brain injury in mice. Neurobiology of Disease 41 (2011) 329–337. Ofer Zohar, Rotem Lavy, Xiaomei Zi, Thomas J. Nelson, Jarin Hongpaisan, Chaim G. Pick, D.L. Alkon

I did my part to support what I believe and to support the research team Dr. Alkon led. Hope this could explain my intention and my contribution to your community.

Thanks and regards.

beyondBet

现在，占领了两个舆论高地， 欢迎关注：

https://finance.yahoo.com/quote/SNPX/community?p=SNPX

https://stocktwits.com/symbol/SNPX